Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Chief Operating Officer | August 16, 2020 | August 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date August 16, 2020 · Filed August 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,167 |
Reported balance
After 2020-08-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-08-16 · Exercise / conversion · Acquired 1,595 · Balance 25,167 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: Includes 733 shares acquired by the Reporting Person on August 14, 2020 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. |
| Common StockSEC Table I · non-derivative | Direct | 24,615 |
Reported balance
After 2020-08-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-08-16 · Tax withholding · Disposed 552 · Balance 24,615 F3: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,595 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,937 |
Reported balance
After 2020-08-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-08-16 · Exercise / conversion · Disposed 1,595 · Balance 23,937 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Includes 733 shares acquired by the Reporting Person on August 14, 2020 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
F3: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,595 shares of Common Stock underlying the Reporting Person's Restricted Stock Units.
F4: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Activision Blizzard, Inc.
Report date August 13, 2019 · Filed August 15, 2019
Section 16 reporting ended · disclosed 2019-08-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.000001 per shareSEC Table I · non-derivative | Direct | 242,886 |
Reported balance
After 2019-08-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-08-13 · Exercise / conversion · Acquired 134,845 · Balance 242,886 |
| Common Stock, par value $0.000001 per shareSEC Table I · non-derivative | Direct | 108,041 |
Reported balance
After 2019-08-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2019-08-13 · Sale · Disposed 134,845 · Balance 108,041 F1: The price in column 4 is a weighted average price. The prices actually received for the stock ranged from $47.74 to $47.98 per share. Mr. Stolz has provided the Company, and upon request, will provide any security holder of the Company or the SEC staff, with information regarding the number of shares sold at each price within that range. F2: Following the transactions reported on this Form 4, Mr. Stolz held (a) 40,955 shares of the Company's common stock and (b) 67,086 performance-vesting restricted stock units, each representing the right to receive one share of the Company's common stock. |
| Employee Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $40.61 · Expires 2026-08-08 | Direct | 44,948 |
Reported balance
After 2019-08-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-08-13 · Exercise / conversion · Disposed 134,845 · Balance 44,948 F3: The exercised options vested on May 30, 2019. The remaining options vest on May 30, 2020, subject to Mr. Stolz's employment through that date. |
Filing footnotes · ownership attribution and instrument terms
F1: The price in column 4 is a weighted average price. The prices actually received for the stock ranged from $47.74 to $47.98 per share. Mr. Stolz has provided the Company, and upon request, will provide any security holder of the Company or the SEC staff, with information regarding the number of shares sold at each price within that range.
F2: Following the transactions reported on this Form 4, Mr. Stolz held (a) 40,955 shares of the Company's common stock and (b) 67,086 performance-vesting restricted stock units, each representing the right to receive one share of the Company's common stock.
F3: The exercised options vested on May 30, 2019. The remaining options vest on May 30, 2020, subject to Mr. Stolz's employment through that date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2020 Filed Aug 18, 2020 23:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022790 · doc4.xml · derivative · entry 3 Stolz Brian M. · CIK 0001524803 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,937 Underlying: Common Stock · 1,595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F4 · derivative.expiration_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 23:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 552 | $28.53 | $15,748.56 |
DisclosureSEC source: 0000899243-20-022790 · doc4.xml · nonDerivative · entry 2 Stolz Brian M. · CIK 0001524803 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,615 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,595 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 23:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 1,595 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-022790 · doc4.xml · nonDerivative · entry 1 Stolz Brian M. · CIK 0001524803 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 733 shares acquired by the Reporting Person on August 14, 2020 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 23:57 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 25,532 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015537 · doc4.xml · derivative · entry 2 Stolz Brian M. · CIK 0001524803 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,532 Underlying: Common Stock · 25,532 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. In general, 6.25% of the RSUs will vest on August 16, 2020 and 6.25% will vest in quarterly installments on the 16th day of February, May, August and November, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through the applicable vesting date. F3 · derivative.expiration_date: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. In general, 6.25% of the RSUs will vest on August 16, 2020 and 6.25% will vest in quarterly installments on the 16th day of February, May, August and November, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through the applicable vesting date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 23:57 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 183,727 | $0.00 Strike: $28.86 | $0.00 |
DisclosureSEC source: 0000899243-20-015537 · doc4.xml · derivative · entry 1 Stolz Brian M. · CIK 0001524803 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,727 Underlying: Common Stock · 183,727 shares Expires 2030-06-02 F1 · derivative.exercise_date: The Option will vest over approximately four years. 1/48th of the shares of Common Stock underlying the Option will vest on a monthly basis after June 3, 2020 (the "Vesting Commencement Date"), such that all of the shares underlying the Option will be vested on the date four (4) years after the Vesting Commencement Date, subject to the Reporting Person's continued Service Relationship (as defined in the Plan) with the Issuer or any of its subsidiaries through the applicable vesting date. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 72,696 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029354 · doc4.xml · derivative · entry 1 Stolz Brian M. · CIK 0001524803 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,696 Underlying: Common Stock · 72,696 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units are convertible to Common Stock on a 1 for 1 basis and have no expiration date. F2 · derivative.exercise_date: The units shall vest as to 25% of the units on February 16, 2021, and as to 1/12th of the units each quarter thereafter for three additional years, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: The units shall vest as to 25% of the units on February 16, 2021, and as to 1/12th of the units each quarter thereafter for three additional years, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| November 13, 2019 Filed Nov 16, 2019 00:23 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 106,469 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-027434 · doc4.xml · derivative · entry 3 Stolz Brian M. · CIK 0001524803 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,469 Underlying: Common Stock · 106,469 shares Expires not disclosed F2 · derivative.exercise_price: Restricted Stock Units are convertible to Common Stock on a 1 for 1 basis and have no expiration date. F3 · derivative.exercise_date: The units shall vest as to 25% of the units on November 16, 2020, and as to 1/12th of the units each quarter thereafter for three additional years, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: Restricted Stock Units are convertible to Common Stock on a 1 for 1 basis and have no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 16, 2019 00:23 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 102,081 | $0.00 Strike: $26.28 | $0.00 |
DisclosureSEC source: 0000899243-19-027434 · doc4.xml · derivative · entry 2 Stolz Brian M. · CIK 0001524803 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,081 Underlying: Common Stock · 102,081 shares Expires 2029-11-12 F1 · derivative.exercise_date: The option shall vest and become exercisable as to 25% of the shares on October 7, 2020, and as to 1/48th of the shares each month thereafter for three additional years, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| November 13, 2019 Filed Nov 16, 2019 00:23 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 22,839 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-027434 · doc4.xml · nonDerivative · entry 1 Stolz Brian M. · CIK 0001524803 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,839 Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 19:06 UTC | Activision Blizzard, Inc. ATVI · Entity 11437 | Exercise / conversionEmployee Stock Options · Derivative | 134,845 | $0.00 Strike: $40.61 | $0.00 |
DisclosureSEC source: 0001708989-19-000052 · wf-form4_156591039385055.xml · derivative · entry 3 Stolz Brian M. · CIK 0001524803 · Former Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,948 Underlying: Common Stock, par value $0.000001 per share · 134,845 shares Expires 2026-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The exercised options vested on May 30, 2019. The remaining options vest on May 30, 2020, subject to Mr. Stolz's employment through that date. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 19:06 UTC | Activision Blizzard, Inc. ATVI · Entity 11437 | SaleCommon Stock, par value $0.000001 per share | 134,845 | $47.80 | $6,445,267.37 |
DisclosureSEC source: 0001708989-19-000052 · wf-form4_156591039385055.xml · nonDerivative · entry 2 Stolz Brian M. · CIK 0001524803 · Former Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,041 F1 · price: The price in column 4 is a weighted average price. The prices actually received for the stock ranged from $47.74 to $47.98 per share. Mr. Stolz has provided the Company, and upon request, will provide any security holder of the Company or the SEC staff, with information regarding the number of shares sold at each price within that range. F2 · balance_after: Following the transactions reported on this Form 4, Mr. Stolz held (a) 40,955 shares of the Company's common stock and (b) 67,086 performance-vesting restricted stock units, each representing the right to receive one share of the Company's common stock. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 19:06 UTC | Activision Blizzard, Inc. ATVI · Entity 11437 | Exercise / conversionCommon Stock, par value $0.000001 per share | 134,845 | $40.61 | $5,476,055.45 |
DisclosureSEC source: 0001708989-19-000052 · wf-form4_156591039385055.xml · nonDerivative · entry 1 Stolz Brian M. · CIK 0001524803 · Former Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 19:02 UTC | Activision Blizzard, Inc. ATVI · Entity 11437 | Tax withholdingCommon Stock, par value $0.000001 per share | 36,405 | $43.56 | $1,585,801.80 |
DisclosureSEC source: 0001708989-19-000016 · wf-form4_155960291735573.xml · nonDerivative · entry 1 Stolz Brian M. · CIK 0001524803 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,041 F1 · shares: On May 30, 2019, 77,360 performance-vesting restricted stock units held by Mr. Stolz vested. Pursuant to the terms of his restricted stock unit award agreement, the Company withheld 36,405 of the shares otherwise deliverable to him in order to satisfy the resulting tax withholding obligation. As the performance conditions underlying this restricted stock unit award were not achieved at the maximum level, 12,674 previously reported restricted stock units did not vest. F2 · balance_after: Following the transaction reported on this Form 4, Mr. Stolz held (a) 40,955 shares of the Company's common stock and (b) 67,086 performance-vesting restricted stock units, each representing the right to receive one share of the Company's common stock. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 19:08 UTC | Activision Blizzard, Inc. ATVI · Entity 11437 | GrantCommon Stock, par value $0.000001 per share | 11,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001352027-18-000064 · wf-form4_154224048462938.xml · nonDerivative · entry 1 Stolz Brian M. · CIK 0001524803 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,120 F1 · shares: This grant was for 11,598 performance-vesting restricted stock units, each representing the right to receive one share of the Company's common stock. The number assumes maximum performance; target performance would result in a release of 9,278 shares of the Company's common stock. The restricted stock units vest in full on March 30, 2022, based upon the level of performance measured by reference to the Company's cumulative operating income for 2019, 2020 and 2021. F2 · balance_after: Following the transactions reported on this Form 4, Mr. Stolz holds 157,120 performance-vesting restricted stock units, each representing the right to receive one share of the Company's common stock. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 18:06 UTC | Activision Blizzard, Inc. ATVI · Entity 11437 | GrantCommon Stock, par value $0.000001 per share | 10,268 | $0.00 | $0.00 |
DisclosureSEC source: 0001352027-17-000041 · edgar.xml · nonDerivative · entry 1 Stolz Brian M. · CIK 0001524803 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,522 F1 · shares: This grant was for 10,268 performance-vesting restricted stock units, each representing the right to receive one share of the Company's common stock. The number assumes maximum performance; target performance would result in a release of 8,214 shares of the Company's common stock. The restricted stock units vest in full on March 30, 2021, based upon the level of performance measured by reference to the Company's cumulative operating income for 2018, 2019 and 2020. F2 · balance_after: Following the transactions reported on this Form 4, Mr. Stolz holds 145,522 performance-vesting restricted stock units, each representing the right to receive one share of the Company's common stock. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 20:07 UTC | Activision Blizzard, Inc. ATVI · Entity 11437 | GrantCommon Stock, par value $0.000001 per share | 15,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001352027-16-000122 · edgar.xml · nonDerivative · entry 1 Stolz Brian M. · CIK 0001524803 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,254 F1 · shares: This grant was for 15,210 performance-vesting restricted stock units, each representing the right to receive one share of the Company's common stock. The number assumes maximum performance; target performance would result in a release of 12,168 shares of the Company's common stock. The restricted stock units vest in full on March 31, 2020, based upon the level of performance measured by reference to the Company's cumulative operating income for 2017, 2018 and 2019. F2 · balance_after: Following the transactions reported on this Form 4, Mr. Stolz holds 135,254 performance-vesting restricted stock units, each representing the right to receive one share of the Company's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.